FY2026 4Q Earnings Presentation
Filed with TSE · · 37 pages · English
p. 3 I. Overview of Financial Results for FYE May 2026 Executive Summary ◼ Consolidated net sales were 50.65 billion yen, a slight increase year-on-year, and EBITDA was 8.02 billion yen, landing with a significant profit increase. ◼ In addition to the net sales contribution from the sale of "Opalmon Tablets," for which assets were succeeded from Ono Pharmaceutical Co., Ltd., the reduction of long-
Daito Pharmaceutical Co., Ltd. on 6ix
In the deck
Earlier from Daito Pharmaceutical
- Notice Regarding the Results and Completion of the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Transaction (ToSTNet-3)
- Summary of Consolidated Financial Results for the Fiscal Year Ended May 31,2026 (Under Japanese GAAP)
- Summary of Consolidated Financial Results for the Six Months Ended November 30, 2025 (Under Japanese GAAP)
- Summary of Consolidated Financial Results for the Three Months Ended August 31, 2024(Based on Japanese GAAP)
- Summary of Consolidated Financial Results for the Year Ended May 31, 2024(Based on Japanese GAAP)
Later from Daito Pharmaceutical
- Execution of JV and Share Transfer Agreement for Transfer of KYORIN Pharmaceutical's Generic Drug Business to JV by Daito, Meiji Seika Pharma and DBJ
- FY2027 1Q Earnings Presentation
- Notice Concerning the Acquisition of Treasury Shares and the Cancellation of Treasury Shares
- [Summary] Summary of Consolidated Financial Results for the Three Months Ended August 31, 2026 (Under Japanese GAAP)
- Notice Regarding Repurchase of Own Shares
Follow Daito Pharmaceutical into a list and get an email when it puts out news.
Follow Daito Pharmaceutical